RxDoctor Payments Data

Jeffrey Jackson

Optometrist · Casa Grande, AZNPI 1003014051

Payments from drug & device makers

$1,113in general payments, 2019–2025

Across 37 payments — averaging $30.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$340
  • Alcon$208
  • Aerie Pharmaceuticals, Inc.$170
  • Glaukos Corporation$115
  • Tarsus Pharmaceuticals, Inc.$67
  • Bausch & Lomb Americas Inc.$58
  • plus $155 from 7 others

What the payments were for

  • Food & beverage$1,113100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,113 in reported general payments places this provider in the 55th percentile of 1,134 optometrist providers in Arizona.

See all optometrist providers in Arizona

Medicare billing

Part B allowed, 2024
$212,532
Medicare patients
1,184
Services billed
2,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost94$58,837
RestasisCyclosporine13$23,284
Latanoprost983$12,193
CombiganBrimonidine Tartrate/Timolol18$12,189
RocklatanNetarsudil Mesylat/Latanoprost17$9,446
Travoprost54$7,613
Brimonidine Tartrate210$5,755
Prednisolone Acetate125$4,644
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol31$4,103
Timolol Maleate352$3,559
Alphagan PBrimonidine Tartrate11$2,122
Loteprednol Etabonate15$1,896
Dorzolamide Hcl98$1,767
Ketorolac Tromethamine43$1,249
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat86$1,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$340$96,432136 claims
Aerie Pharmaceuticals, Inc.Rocklatan$170$9,44617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,134 optometrist providers in Arizona.

Other optometrist in Casa Grande

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →